Loading
Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival.
Amer Zeidan leads the myelodysplastic syndromes programme at Yale Cancer Center. He was the lead investigator of VERONA, the phase 3 trial of venetoclax plus azacitidine against azacitidine alone in newly diagnosed higher-risk MDS, and presented its results in 2024: the combination did not improve overall survival. He publishes widely on MDS treatment patterns, health outcomes and trial endpoints.
| Title | Journal | Year |
|---|---|---|
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 420 citations on Europe PMC. | New England Journal of Medicine | 2020 |
| Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 150 citations on Europe PMC. | Journal of Clinical Oncology | 2021 |
| COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 140 citations on Europe PMC. | The Lancet | 2023 |
COMMANDS moved luspatercept from second line (after ESA failure, MEDALIST trial) to first line, offering transfusion-dependent lower-risk MDS patients a better chance of transfusion freedom from the start. It changed guidelines and labels in 2023. Erythropoietin remains a reasonable and cheaper option for patients without ring sideroblasts or with low transfusion burden.
One of the most cited papers Europe PMC returns for Amer M. Zeidan at Yale Cancer Center / Smilow Cancer Hospital, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Amer M. Zeidan at Yale Cancer Center / Smilow Cancer Hospital, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Myelodysplastic syndromes / neoplasms (MDS) and the tags mds, trialist.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag mds.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).